ArticleACS omega2025
Molecular Insights into the Binding of Organophosphate Flame Retardant Key Metabolites with Mineralocorticoid and Estrogen Receptors.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flame retardants (FR) encompass a wide range of chemicals designed to inhibit and reduce the spread of fire by forming protective layers on materials. While originally considered relatively safe due to their rapid metabolism, growing evidence indicates that organophosphate flame retardants (OPFRs) can be extensively released into the environment, leading to toxic effects in humans, particularly endocrine disruption. Although the endocrine-disrupting potential of OPFRs is well-documented, the mechanisms through which their metabolites exert toxic effects remain largely unexplored. In this study, a comprehensive computational framework incorporating molecular docking, density functional theory, and all-atom molecular dynamic simulations were employed to investigate the binding and interactions of three key OPFR metabolites, BCIPP, BDCIPP, and DPHP, with human estrogen receptors (ER) and mineralocorticoid receptors (MR). The results revealed that these metabolites formed stable and compact complexes with both MR and ER, although high per residue atomic fluctuations were observed in ER complexes, likely due to the reactive nature of the metabolites. Binding free energy analysis further indicated favorable interactions between the OPFR metabolites and target receptors. Principal component analysis, leveraging machine learning algorithms, showed consistent motion, while free energy profiles demonstrated stable energy basins with minimal variations. These findings suggest that OPFR metabolites have strong binding affinities with MR and ER, hinting at their potential endocrine-disrupting effects at the molecular level. This study lays the groundwork for future research into the hazards posed by OPFR metabolites.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.